Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Gil Omenn AI simulator
(@Gil Omenn_simulator)
Hub AI
Gil Omenn AI simulator
(@Gil Omenn_simulator)
Gil Omenn
Gilbert S. Omenn (born August 30, 1941) is an American medical doctor and researcher. He currently is the Harold T. Shapiro Distinguished University Professor at the University of Michigan; Professor of Computational medicine & bioinformatics, Molecular medicine & genetics, Human genetics, and Public health; and the Director of the UM Center for Computational Medicine & Bioinformatics. He is the discoverer of Omenn syndrome, a genetic disorder that is fatal in infancy unless treated. Omenn has served as editor of the Annual Review of Public Health from 1990–1996. and as president of the American Association for the Advancement of Science (AAAS). He has published more than 600 peer-reviewed papers and reviews and is the author or editor of 18 books.
Omenn received a B.A. from Princeton University (class of 1961) and an M.D. from Harvard Medical School (1965). He interned and did his residency at Massachusetts General Hospital.
Omenn worked with Christian B. Anfinsen at the National Institutes of Health from 1967-1969, doing research as part of military service. In 1969, he joined the University of Washington (UW) in Seattle, Washington as a fellow, working with Arno G. Motulsky in medical genetics. He went on to earn a Ph.D. in genetics from the University of Washington, which he received in 1972.
As a fourth-year student, Omenn studied prenatal diagnosis of inherited conditions. He discovered what is now known as Omenn syndrome, a genetic disorder characterized by the loss of T-cell function. It is generally fatal in infancy, but some cases have responded to treatment.
In 1971 Omenn joined the faculty of medical genetics at the University of Washington. Omenn was appointed as a White House Fellow in 1973-1974, under Presidents Richard Nixon and Gerald Ford. He was one of two staff on Nixon's Project Independence, looking for ways to lessen America's dependence on imported oil. He was also part of a diplomatic mission to convince France not to share nuclear information with Pakistan. Omenn worked with the Atomic Energy Commission on international nuclear policy.
As of 1974 Omenn was first appointed to the National Cancer Advisory Board, as an alternate for Frank Press, Director of the Office of Science and Technology Policy. Omenn's title was Assistant Director of Human Resources, Office of Science and Technology Policy. During 1977-1981, Omenn worked with the Carter administration, first as an assistant to Frank Press, the President's advisor on Science and Technology Policy, and then as Associate Director in the Office of Management and Budget.
Omenn founded the Robert Wood Johnson Clinical Scholars Program at the University of Washington in 1975. He was a Howard Hughes Medical Institute investigator for 1976-1977. He was promoted to a full professorship in medicine in 1979. While at UW, Omenn began working with the Fred Hutchinson Cancer Research Center in Seattle, to conduct clinical trials in cancer prevention. He served as principal investigator of the beta-Carotene and Retinol Efficacy Trial (CARET) seeking preventive agents against lung cancer and heart disease.
In 1981, he was a visiting professor at the Woodrow Wilson School of Princeton University and the Brookings Institution's first Science, Technology, and Policy Fellow.
Gil Omenn
Gilbert S. Omenn (born August 30, 1941) is an American medical doctor and researcher. He currently is the Harold T. Shapiro Distinguished University Professor at the University of Michigan; Professor of Computational medicine & bioinformatics, Molecular medicine & genetics, Human genetics, and Public health; and the Director of the UM Center for Computational Medicine & Bioinformatics. He is the discoverer of Omenn syndrome, a genetic disorder that is fatal in infancy unless treated. Omenn has served as editor of the Annual Review of Public Health from 1990–1996. and as president of the American Association for the Advancement of Science (AAAS). He has published more than 600 peer-reviewed papers and reviews and is the author or editor of 18 books.
Omenn received a B.A. from Princeton University (class of 1961) and an M.D. from Harvard Medical School (1965). He interned and did his residency at Massachusetts General Hospital.
Omenn worked with Christian B. Anfinsen at the National Institutes of Health from 1967-1969, doing research as part of military service. In 1969, he joined the University of Washington (UW) in Seattle, Washington as a fellow, working with Arno G. Motulsky in medical genetics. He went on to earn a Ph.D. in genetics from the University of Washington, which he received in 1972.
As a fourth-year student, Omenn studied prenatal diagnosis of inherited conditions. He discovered what is now known as Omenn syndrome, a genetic disorder characterized by the loss of T-cell function. It is generally fatal in infancy, but some cases have responded to treatment.
In 1971 Omenn joined the faculty of medical genetics at the University of Washington. Omenn was appointed as a White House Fellow in 1973-1974, under Presidents Richard Nixon and Gerald Ford. He was one of two staff on Nixon's Project Independence, looking for ways to lessen America's dependence on imported oil. He was also part of a diplomatic mission to convince France not to share nuclear information with Pakistan. Omenn worked with the Atomic Energy Commission on international nuclear policy.
As of 1974 Omenn was first appointed to the National Cancer Advisory Board, as an alternate for Frank Press, Director of the Office of Science and Technology Policy. Omenn's title was Assistant Director of Human Resources, Office of Science and Technology Policy. During 1977-1981, Omenn worked with the Carter administration, first as an assistant to Frank Press, the President's advisor on Science and Technology Policy, and then as Associate Director in the Office of Management and Budget.
Omenn founded the Robert Wood Johnson Clinical Scholars Program at the University of Washington in 1975. He was a Howard Hughes Medical Institute investigator for 1976-1977. He was promoted to a full professorship in medicine in 1979. While at UW, Omenn began working with the Fred Hutchinson Cancer Research Center in Seattle, to conduct clinical trials in cancer prevention. He served as principal investigator of the beta-Carotene and Retinol Efficacy Trial (CARET) seeking preventive agents against lung cancer and heart disease.
In 1981, he was a visiting professor at the Woodrow Wilson School of Princeton University and the Brookings Institution's first Science, Technology, and Policy Fellow.